Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 8, 2025BloodOpen Access

The development of FT839: An off-the-shelf CD19xCD38 dual-CAR T cell for the treatment of multiple myeloma

View Full Paper
Ask AI
Bookmark
Share

Authors

CDCarissa DegeBHBryan HancockDLDan Lu

Discussion

Loading...

Member takes

Overview

Observational analysis shows enhanced cytotoxicity and anti-tumor activity in multiple myeloma using dual-CAR T cells and monoclonal antibodies, indicating a promising treatment option.

Key Points

  • FT839 demonstrates significant anti-tumor activity against multiple myeloma targets, achieving over 90% cytotoxicity with dual-CAR targeting.
  • Cytotoxicity assays validated the effectiveness of FT839 against cell lines like RPMI-8226 and H929, showcasing durable responses.
  • Combining FT839 with monoclonal antibodies and T cell engagers resulted in enhanced therapeutic outcomes for patients.
  • This engineered iPSC-derived CAR T cell addresses tumor heterogeneity, offering a novel solution for patients without complex manufacturing hurdles.

Cite This Study

Dege et al. (2025) studied this question.

synapsesocial.com/papers/69362f744fa91c937236e2c9https://doi.org/10.1182/blood-2025-7631
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Targeting of tumor antigen CD38 and stress antigens MICA/B by CAR T cells provides a unique approach for the comprehensive treatment of multiple myeloma2025
  2. 2CAR-T cells manufactured after multiple myeloma triplet or quadruplet induction therapy have reduced functionality and an altered composition2025
  3. 3The allogeneic fully human anti-CD38-CAR-γδ T cells enable off-the-shelf CAR-T cell therapy for myeloma2025
  4. 4Preclinical development of an optimized manufacturing, CRISPR-edited, fully non-viral 1XX-enhanced anti-BCMA CAR-T therapy for multiple myeloma2025
  5. 5[Next-generation CAR gene-modified cell therapy: overcoming resistance and exploring novel applications].2025